Liquid Biopsy
•25 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (25)
%
| Company | Market Cap | Price |
|---|---|---|
|
Signatera and related cfDNA tests operate as liquid biopsy diagnostic tests detecting circulating tumor DNA.
|
$22.07B |
$161.61
+0.94%
|
|
Quest Diagnostics offers liquid biopsy diagnostic tests (e.g., Haystack MRD) and other circulating biomarker-based assays, a major liquid biopsy product category.
|
$20.55B |
$184.07
+0.97%
|
|
Liquid biopsy sample preparation capabilities and related diagnostic applications.
|
$10.49B |
$46.85
-1.10%
|
|
Core product category: Liquid biopsy testing platform used for cancer detection, MRD monitoring, and early screening.
|
$7.96B |
$64.22
-3.53%
|
|
Whole-genome sequencing-based MRD testing (ctDNA) constitutes a liquid biopsy approach for minimal residual disease monitoring.
|
$2.73B |
$34.80
-0.66%
|
|
Galleri is a liquid biopsy-based cfDNA methylation test that detects multiple cancers, fitting the Liquid Biopsy investable theme.
|
$2.38B |
$66.13
-7.38%
|
|
Liquid biopsy and MRD-focused NGS diagnostics indicate a liquid biopsy product line.
|
$1.87B |
$31.19
-6.39%
|
|
OPKO's 4Kscore test represents a blood-based diagnostic test (liquid biopsy concept) offered through BioReference operations.
|
$1.20B |
$1.51
-3.21%
|
|
PanTracer liquid biopsy and RaDaR MRD assays represent major liquid biopsy offerings expanding detection in solid tumors and MRD.
|
$1.17B |
$9.10
+1.56%
|
|
NeXT Personal is a tumor-informed ultra-sensitive liquid biopsy MRD test, i.e., a liquid biopsy product/service.
|
$717.20M |
$8.12
-6.67%
|
|
Liquid biopsy / ctDNA-based testing capabilities (Precise MRD) focused on highly sensitive tumor profiling.
|
$709.77M |
$7.72
+0.78%
|
|
Liquid biopsy capabilities (MSK-ACCESS) as part of the diagnostic analytics offerings.
|
$277.71M |
$4.18
-7.32%
|
|
Blood proteomics development aiming at liquid biopsy applications aligns with OraSure's expansion into blood-based diagnostics.
|
$238.61M |
$3.20
+0.31%
|
|
NIS4 is a non-invasive, blood-based diagnostic modality consistent with the liquid biopsy investable theme.
|
$212.11M |
$4.25
-2.29%
|
|
Insighta FRAGMA liquid biopsy enables multi-cancer early detection, a key diagnostic technology.
|
$169.77M |
$13.89
-3.94%
|
|
GraftAssure uses donor-derived cfDNA in a liquid biopsy context for transplant rejection testing.
|
$111.25M |
$3.89
+2.37%
|
|
brPROPHET MRD and MCED platforms are liquid biopsy tests using ctDNA, a direct diagnostic product line.
|
$86.30M |
$8.36
-4.46%
|
|
Biodesix provides blood-based diagnostic tests (Nodify and VeriStrat), i.e., liquid biopsy tests for lung nodules/cancer.
|
$53.64M |
$7.32
-6.75%
|
|
VolitionRx's Nu.Q platform constitutes a liquid biopsy diagnostic approach that measures circulating nucleosomes for cancer and NETosis-related conditions.
|
$47.81M |
$0.46
-10.75%
|
|
The company uses a diagnostic test (ECHO) for ecDNA in its trials, aligning with the Liquid Biopsy category.
|
$27.53M |
$1.23
-0.81%
|
|
MSC Lung Test is a blood-based diagnostic approach (miRNA signature) consistent with liquid biopsy testing.
|
$23.64M |
$1.47
+2.85%
|
|
MDxHealth offers liquid biopsy diagnostic tests (Select mdx, ExoDx) for prostate cancer and urinary tract infections, classifying them under Liquid Biopsy.
|
$11.13M |
$4.08
-7.06%
|
|
Core product line: liquid biopsy diagnostics using RNA in blood (VitaGuard MRD integration).
|
$9.32M |
$5.19
-3.71%
|
|
RPIDD liquid biopsy diagnostic and the APOE Genotyping test reflect Blood-based Brain Health Diagnostics / Liquid Biopsy capabilities.
|
$9.08M |
$1.66
-30.83%
|
|
PancAlert is a blood-based, liquid biopsy diagnostic using biomarker panels for pancreatic cancer screening.
|
$1.02M |
$1.60
|
Loading industry metrics...
Loading comparison data...
